Merit Medical Systems (NASDAQ:MMSI) Issues FY 2025 Earnings Guidance

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 3.280-3.410 for the period, compared to the consensus estimate of 3.350. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Merit Medical Systems Stock Up 0.9%

Shares of NASDAQ:MMSI traded up $0.80 during trading on Monday, reaching $93.77. 488,035 shares of the stock traded hands, compared to its average volume of 650,582. The stock has a market cap of $5.54 billion, a P/E ratio of 45.97, a price-to-earnings-growth ratio of 2.34 and a beta of 0.66. Merit Medical Systems has a 52-week low of $80.02 and a 52-week high of $111.45. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. The stock has a 50-day moving average of $94.51 and a two-hundred day moving average of $99.54.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The medical instruments supplier reported $0.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.75 by $0.11. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The firm had revenue of $355.35 million for the quarter, compared to the consensus estimate of $352.57 million. During the same period in the prior year, the company posted $0.77 earnings per share. The company's quarterly revenue was up 9.8% on a year-over-year basis. As a group, sell-side analysts expect that Merit Medical Systems will post 3.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MMSI has been the topic of a number of research reports. Barrington Research dropped their price target on Merit Medical Systems from $111.00 to $103.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Wells Fargo & Company restated an "overweight" rating and set a $108.00 price target (up from $106.00) on shares of Merit Medical Systems in a research note on Wednesday, May 21st. Canaccord Genuity Group set a $112.00 price objective on shares of Merit Medical Systems and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Piper Sandler reissued an "overweight" rating and issued a $110.00 price objective (up previously from $106.00) on shares of Merit Medical Systems in a report on Friday, May 23rd. Finally, Robert W. Baird reduced their target price on shares of Merit Medical Systems from $111.00 to $110.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Merit Medical Systems currently has an average rating of "Moderate Buy" and a consensus target price of $109.11.

Insiders Place Their Bets

In related news, CEO Fred P. Lampropoulos sold 400 shares of the firm's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $95.61, for a total transaction of $38,244.00. Following the completion of the transaction, the chief executive officer now directly owns 1,045,628 shares of the company's stock, valued at approximately $99,972,493.08. This trade represents a 0.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David Floyd sold 3,515 shares of the business's stock in a transaction on Friday, May 30th. The stock was sold at an average price of $94.16, for a total transaction of $330,972.40. Following the completion of the sale, the director now owns 4,880 shares in the company, valued at approximately $459,500.80. The trade was a 41.87% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 70,415 shares of company stock worth $6,748,214. Corporate insiders own 3.20% of the company's stock.

Institutional Investors Weigh In On Merit Medical Systems

An institutional investor recently raised its position in Merit Medical Systems stock. AQR Capital Management LLC lifted its holdings in Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) by 7.3% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 16,361 shares of the medical instruments supplier's stock after purchasing an additional 1,114 shares during the quarter. AQR Capital Management LLC's holdings in Merit Medical Systems were worth $1,730,000 at the end of the most recent quarter. 99.66% of the stock is currently owned by hedge funds and other institutional investors.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.